Incapacitating solar urticaria: successful treatment with omalizumab
Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
Saved in:
Main Authors: | Kieselova,Katarina, Santiago,Felicidade, Henrique,Martinha |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Dermatologia
2019
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300331 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Urticaria and angioedema as possible reactions of omalizumab
by: Ozbagcivan,Ozlem, et al.
Published: (2018) -
Successful off-label use of omalizumab in a child with chronic spontaneous urticaria
by: Gonçalves,Tânia, et al.
Published: (2024) -
Omalizumab and new therapeutic targets in chronic spontaneous urticaria
by: Pereira,Ana S., et al.
Published: (2024) -
Case for diagnosis. Solitary violaceous nodule on the toe
by: Kieselova,Katarina, et al.
Published: (2018) -
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
by: Kocatürk,Emek, et al.
Published: (2022)